Quantification of SAA1 and SAA2 in lung cancer plasma using the isotype-specific PRM assays

Proteomics

Volumn 15, Issue 18, 2015, Pages 3116-3125

  Kim, Yeoun Jin ^a   Gallien, Sebastien ^a   El Khoury, Victoria ^a   Goswami, Panchali ^a   Sertamo, Katriina ^a   Schlesser, Marc ^b   Berchem, Guy ^a,b   Domon, Bruno ^a  

^a LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^b CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

Author keywords

Cancer biomarkers; Plasma; PRM; Protein assays; Technology

Indexed keywords

GENOMIC DNA; PROTEIN VARIANT; SERUM AMYLOID A; SERUM AMYLOID A1; SERUM AMYLOID A2; UNCLASSIFIED DRUG; TUMOR MARKER;

AMINO ACID SEQUENCE; ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS REACTION; GENOTYPE; GENOTYPING TECHNIQUE; HUMAN; IMMUNOASSAY; MASS SPECTROMETRY; NON SMALL CELL LUNG CANCER; PARALLEL REACTION MONITORING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; BLOOD; CASE CONTROL STUDY; ISOTOPE LABELING; LUNG TUMOR; MOLECULAR GENETICS; PROCEDURES; SEQUENCE ALIGNMENT;

AMINO ACID SEQUENCE; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; HUMANS; ISOTOPE LABELING; LUNG NEOPLASMS; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; SEQUENCE ALIGNMENT; SERUM AMYLOID A PROTEIN;

EID: 84941735922     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201400382     Document Type: Article

References (28)

1. Picotti, P., Rinner, O., Stallmach, R., Dautel, F. et al., High-throughput generation of selected reaction-monitoring assays for proteins and proteomes. Nat. Methods 2010, 7, 43-46.
2. Gallien, S., Duriez, E., Domon, B., Selected reaction monitoring applied to proteomics. J. Mass Spectrom. 2011, 46, 298-312.
3. Gallien, S., Duriez, E., Crone, C., Kellmann, M. et al., Targeted proteomic quantification on quadrupole-orbitrap mass spectrometer. Mol. Cell. Proteomics 2012, 11, 1709-1723.
4. Kim, Y. J., Gallien, S., vanOostrum, J., Domon, B., Targeted proteomics strategy applied to biomarker evaluation. Proteomics Clin. Appl. 2013, 7, 739-747.
5. Gallien, S., Bourmaud, A., Kim, S. Y., Domon, B., Technical considerations for large-scale parallel reaction monitoring analysis. J. Proteomics 2014, 100, 147-159.
6. Paret, C., Schon, Z., Szponar, A., Kovacs, G., Inflammatory protein serum amyloid A1 marks a subset of conventional renal cell carcinomas with fatal outcome. Eur. Urol. 2010, 57, 859-866.
7. Kimura, M., Tomita, Y., Imai, T., Saito, T. et al., Significance of serum amyloid A on the prognosis in patients with renal cell carcinoma. Cancer 2001, 92, 2072-2075.
8. Wood, S. L., Rogers, M., Cairns, D. A., Paul, A. et al., Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer. Br. J. Cancer 2010, 103, 101-111.
9. Khan, N., Cromer, C. J., Campa, M., Patz, E. F., Jr., Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma. Cancer 2004, 101, 379-384.
10. Gao, W. M., Kuick, R., Orchekowski, R. P., Misek, D. E. et al., Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. BMC Cancer 2005, 5: 110.
11. Cho, W. C., Yip, T. T., Cheng, W. W., Au, J. S., Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis. Br. J. Cancer 2010, 102, 1731-1735.
12. Sung, H. J., Jeon, S. A., Ahn, J. M., Seul, K. J. et al., Large-scale isotype-specific quantification of Serum amyloid A 1/2 by multiple reaction monitoring in crude sera. J. Proteomics 2012, 75, 2170-2180.
13. Cremona, M., Calabro, E., Randi, G., DeBortoli, M. et al., Elevated levels of the acute-phase serum amyloid are associated with heightened lung cancer risk. Cancer 2010, 116, 1326-1335.
14. Milan, E., Lazzari, C., Anand, S., Floriani, I. et al., SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors. J. Proteomics 2012, 76 Spec No, 91-101.
15. Carbone, D. P., Ding, K., Roder, H., Grigorieva, J. et al., Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial. J. Thorac. Oncol. 2012, 7, 1653-1660.
16. Garrisi, V. M., Bongarzone, I., Mangia, A., Cremona, M. et al., Characterization of a serum protein pattern from NSCLC patients treated with Gefitinib. Clin. Biochem. 2011, 44, 936-940.
17. Mattarollo, S. R., Smyth, M. J., A novel axis of innate immunity in cancer. Nat. Immunol. 2010, 11, 981-982.
18. Indovina, P., Marcelli, E., Maranta, P., Tarro, G., Lung cancer proteomics: recent advances in biomarker discovery. Int. J. Proteomics 2011, 2011, 726-869.
19. Sung, H. J., Ahn, J. M., Yoon, Y. H., Rhim, T. Y. et al., Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J. Proteome Res. 2011, 10, 1383-1395.
20. Kim, Y. J., Sertamo, K., Pierrard, M. A., Mesmin, C. et al., Verification of the biomarker candidates for non-small-cell lung cancer using a targeted proteomics approach. J. Proteome Res. 2015, 14, 1412-1419.
21. Percy, A. J., Chambers, A. G., Yang, J., Hardie, D. B., Borchers, C. H., Advances in multiplexed MRM-based protein biomarker quantitation toward clinical utility. Biochim. Biophys. Acta 2014, 1844, 917-926.
22. Kushnir, M. M., Rockwood, A. L., Roberts, W. L., Abraham, D. et al., Measurement of thyroglobulin by liquid chromatography-tandem mass spectrometry in serum and plasma in the presence of antithyroglobulin autoantibodies. Clin. Chem. 2013, 59, 982-990.
23. Wan, K. X., Vidavsky, I., Gross, M. L., Comparing similar spectra: from similarity index to spectral contrast angle. J. Am. Soc. Mass Spectrom. 2002, 13, 85-88.
24. Betts, J. C., Edbrooke, M. R., Thakker, R. V., Woo, P., The human acute-phase serum amyloid A gene family: structure, evolution and expression in hepatoma cells. Scand. J. Immunol. 1991, 34, 471-482.
25. Gallien, S., Duriez, E., Demeure, K., Domon, B., Selectivity of LC-MS/MS analysis: implication for proteomics experiments. J. Proteomics 2013, 81, 148-158.
26. Booth, D. R., Booth, S. E., Gillmore, J. D., Hawkins, P. N., Pepys, M. B., SAA1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid 1998, 5, 262-265.
27. Baba, S., Masago, S. A., Takahashi, T., Kasama, T. et al., A novel allelic variant of serum amyloid A, SAA1 gamma: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum. Mol. Genet. 1995, 4, 1083-1087.
28. DeSanto, C., Arscott, R., Booth, S., Karydis, I. et al., Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. Nat. Immunol. 2010, 11, 1039-1046.